Merck's Rosenblatt ponders innovation investment's 'grand experiment'
This article was originally published in Scrip
There is a grand experiment currently underway, triggered initially by the 2008 economic downturn, with drug makers having to decide whether to plunk their money down on the side of innovative technologies – gambling between hitting the jackpot or going bust – or to pull back and play it safe, said Merck Chief Medical Officer Dr Michael Rosenblatt.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.